flecainide has been researched along with Auricular Flutter in 104 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide acetate instant release (LI) has been prescribed for years in the prevention of atrial fibrillation (AF) relapse after sinus rate conversion." | 9.12 | [Flecainide controlled-release for prevention of atrial fibrillation relapse]. ( Chatelin, A; Jaillon, P; Mary-Krause, M; Simon, T; Thuault, M, 2006) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 9.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "This study compared the efficacy and safety of intravenous flecainide and ibutilide for immediate cardioversion of atrial fibrillation (AF)." | 9.11 | Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. ( Aicher, F; Bachleitner, T; Eisserer, G; Gatterer, E; Grander, W; Heinze, G; Kühn, P; Lang, W; Niemeth, C; Reisinger, J; Siostrzonek, P; Vanicek, T, 2004) |
| "Seventy-one consecutive patients with paroxysmal or chronic AF, in whom flecainide infusion (2 mg/kg body weight, intravenously) determined the transformation of AF into common atrial flutter (positive response), were randomized to receive one of the following treatments: oral pharmacologic treatment with flecainide (group A, n = 23); the hybrid treatment (catheter ablation of the inferior vena cava-tricuspid annulus isthmus, plus oral flecainide) (group B, n = 24); or catheter ablation of the isthmus only (group C, n = 24)." | 9.09 | Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; La Rocca, V; Maresca, F; Nocerino, P; Stabile, E; Stabile, G; Turco, P; Vitale, DF, 2001) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 9.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the efficacy and long-term tolerability of flecainide acetate versus quinidine, 239 patients with paroxysmal atrial fibrillation were prospectively treated with flecainide (n = 122) or quinidine (n = 117) in an open-label, randomized trial." | 9.08 | Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. ( Coumel, P; Dorian, P; Hohnloser, SH; Naccarelli, GV, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 9.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 9.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2)." | 9.07 | Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. ( DaTorre, SD; Hougham, AJ; McCarville, SE; Platt, ML; Pritchett, EL, 1991) |
| "To evaluate the efficacy of flecainide acetate in the prevention of paroxysmal atrial fibrillation and flutter, 43 patients (23 men) (mean age 53 years) were randomized blindly to receive either placebo or 150 mg of flecainide twice per day for consecutive periods of 3 months." | 9.07 | Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. ( Hellemann, H; Pietersen, AH, 1991) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 9.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "In a single-blind randomized study, the efficacy of intravenous flecainide (2 mg/kg/10 minutes) versus verapamil (10 mg/1 minute) was assessed in 40 patients with paroxysmal atrial fibrillation (AF) or atrial flutter (AFI)." | 9.06 | Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Kingma, JH; Lie-A-Huen, L; Mast, EG; Suttorp, MJ, 1989) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 8.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 8.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "A 62 year old Caucasian man with a history of paroxysmal atrial fibrillation treated with flecainide, presented with atrial flutter with 1:1 conduction to the ventricles and was cardioverted." | 8.31 | Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report. ( Ganesan, AN; Lahiri, A; Martin, DK; Quah, J; Tiver, KD, 2023) |
| "Oral and intravenous flecainide is recommended for cardioversion of atrial fibrillation." | 8.12 | Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. ( Aksoy, I; Al-Windy, N; Badings, E; Belardinelli, L; Camm, AJ; Crijns, HJGM; Elvan, A; Kowey, PR; Madhavapeddi, P; Ruskin, JN; Tuininga, YS; Van Gelder, IC, 2022) |
| "Flecainide, a widely prescribed class IC agent used to treat atrial arrhythmias, can in rare cases cause 1:1 atrial flutter with rapid conduction." | 8.02 | Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion. ( Colangelo, T; Ho, R; Johnson, D, 2021) |
| "Flecainide pill-in-the-pocket therapy is a pharmacologic treatment option for patients with infrequent episodes of symptomatic atrial fibrillation." | 7.96 | Paroxysmal Atrial Fibrillation on Flecainide Therapy. ( Gavin, JL; Kim, SS; Peigh, GS, 2020) |
| "Class Ic antiarrhythmic agents flecainide and propafenone are amongst the drugs most frequently prescribed to control atrial arrhythmias, in particular atrial fibrillation (AF)." | 7.88 | 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. ( Cervellin, G; Comelli, I; Pigna, F, 2018) |
| "Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise." | 7.76 | Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. ( Gandhi, MM; Lloyd, G; Taylor, R, 2010) |
| " We evaluated frequency-dependence of excitability and refractoriness before and after flecainide or procainamide administration in relation to termination of reentrant atrial flutter." | 7.68 | Sustained atrial flutter around the tricuspid valve in pigs: differentiation of procainamide (class IA) from flecainide (class IC) and their rate-dependent effects. ( Bel, KJ; Crijns, HJ; de Langen, CD; Ebels, T; Grandjean, JG; Lie, KI; Wesseling, H, 1993) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 7.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II)." | 7.68 | Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. ( Hansen, FA; Pedersen, AK; Rasmussen, J; Sihm, I; Thygesen, K, 1990) |
| "Fifty-one consecutive patients with atrial tachycardia [atrial fibrillation (FA) 37, atrial flutter (Fl) 10, tachycardia (TSA) 4] received a single 2 mg/kg dose of flecainide injected intravenously over 5 to 10 minutes." | 7.67 | [Reduction of auricular fibrillation and tachycardia using intravenous flecainide]. ( Aumont, MC; Boujon, B; Charlier, P; Cohen-Solal, A; Dahan, M; Farinotti, P; Jaeger, P; Juliard, JM, 1987) |
| "The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy." | 5.33 | Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; El Jamal, B; Greco, L; La Rocca, V; Messina, V; Nocerino, P; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 2005) |
| " The administration of flecainide, dosage 1." | 5.28 | [A case of atrial paralysis during the use of intravenous flecainide acetate]. ( Pardini, E; Tognarini, S, 1989) |
| "Flecainide acetate instant release (LI) has been prescribed for years in the prevention of atrial fibrillation (AF) relapse after sinus rate conversion." | 5.12 | [Flecainide controlled-release for prevention of atrial fibrillation relapse]. ( Chatelin, A; Jaillon, P; Mary-Krause, M; Simon, T; Thuault, M, 2006) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 5.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "This study compared the efficacy and safety of intravenous flecainide and ibutilide for immediate cardioversion of atrial fibrillation (AF)." | 5.11 | Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. ( Aicher, F; Bachleitner, T; Eisserer, G; Gatterer, E; Grander, W; Heinze, G; Kühn, P; Lang, W; Niemeth, C; Reisinger, J; Siostrzonek, P; Vanicek, T, 2004) |
| "Seventy-one consecutive patients with paroxysmal or chronic AF, in whom flecainide infusion (2 mg/kg body weight, intravenously) determined the transformation of AF into common atrial flutter (positive response), were randomized to receive one of the following treatments: oral pharmacologic treatment with flecainide (group A, n = 23); the hybrid treatment (catheter ablation of the inferior vena cava-tricuspid annulus isthmus, plus oral flecainide) (group B, n = 24); or catheter ablation of the isthmus only (group C, n = 24)." | 5.09 | Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; La Rocca, V; Maresca, F; Nocerino, P; Stabile, E; Stabile, G; Turco, P; Vitale, DF, 2001) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 5.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "In order to compare the efficacy and long-term tolerability of flecainide acetate versus quinidine, 239 patients with paroxysmal atrial fibrillation were prospectively treated with flecainide (n = 122) or quinidine (n = 117) in an open-label, randomized trial." | 5.08 | Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. ( Coumel, P; Dorian, P; Hohnloser, SH; Naccarelli, GV, 1996) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 5.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "To evaluate the efficacy of flecainide acetate in the prevention of paroxysmal atrial fibrillation and flutter, 43 patients (23 men) (mean age 53 years) were randomized blindly to receive either placebo or 150 mg of flecainide twice per day for consecutive periods of 3 months." | 5.07 | Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. ( Hellemann, H; Pietersen, AH, 1991) |
| "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2)." | 5.07 | Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. ( DaTorre, SD; Hougham, AJ; McCarville, SE; Platt, ML; Pritchett, EL, 1991) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 5.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 5.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "In a single-blind randomized study, the efficacy and safety of intravenous propafenone (2 mg/kg body weight per 10 min) versus flecainide (2 mg/kg per 10 min) were assessed in 50 patients with atrial fibrillation or flutter." | 5.06 | The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Jessurun, ER; Kingma, JH; Lie, KI; Lie-A-Huen, L; Suttorp, MJ; van Hemel, NM, 1990) |
| "In a single-blind randomized study, the efficacy of intravenous flecainide (2 mg/kg/10 minutes) versus verapamil (10 mg/1 minute) was assessed in 40 patients with paroxysmal atrial fibrillation (AF) or atrial flutter (AFI)." | 5.06 | Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Kingma, JH; Lie-A-Huen, L; Mast, EG; Suttorp, MJ, 1989) |
| " In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin." | 4.81 | [Protocols for the treatment of supraventricular tachycardias in the fetus]. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Stoutenbeek, P, 2001) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 4.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| " These antiarrhythmics, prescribed to prevent atrial fibrillation (3 patients) and atrial flutter (5 patients), were flecainide in 4 cases, propafenone in 2 cases and cibenzoline and hydroquinidine respectively associated with digitoxine and propranolol." | 4.79 | [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications]. ( Aouate, P; Benassar, A; Fontaine, G; Frank, R; Jacquemin, M; Laborde, JP; Tageddine, R; Tonet, J; Turlure, A, 1995) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 4.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "A 62 year old Caucasian man with a history of paroxysmal atrial fibrillation treated with flecainide, presented with atrial flutter with 1:1 conduction to the ventricles and was cardioverted." | 4.31 | Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report. ( Ganesan, AN; Lahiri, A; Martin, DK; Quah, J; Tiver, KD, 2023) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "Oral and intravenous flecainide is recommended for cardioversion of atrial fibrillation." | 4.12 | Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. ( Aksoy, I; Al-Windy, N; Badings, E; Belardinelli, L; Camm, AJ; Crijns, HJGM; Elvan, A; Kowey, PR; Madhavapeddi, P; Ruskin, JN; Tuininga, YS; Van Gelder, IC, 2022) |
| "Flecainide, a widely prescribed class IC agent used to treat atrial arrhythmias, can in rare cases cause 1:1 atrial flutter with rapid conduction." | 4.02 | Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion. ( Colangelo, T; Ho, R; Johnson, D, 2021) |
| "Flecainide pill-in-the-pocket therapy is a pharmacologic treatment option for patients with infrequent episodes of symptomatic atrial fibrillation." | 3.96 | Paroxysmal Atrial Fibrillation on Flecainide Therapy. ( Gavin, JL; Kim, SS; Peigh, GS, 2020) |
| "Class Ic antiarrhythmic agents flecainide and propafenone are amongst the drugs most frequently prescribed to control atrial arrhythmias, in particular atrial fibrillation (AF)." | 3.88 | 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. ( Cervellin, G; Comelli, I; Pigna, F, 2018) |
| "A patient taking regular flecainide for paroxysmal atrial fibrillation presented with broad complex tachycardia and circulatory compromise." | 3.81 | Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination. ( Apps, A; Fellows, S; Jones, M; Miller, CP, 2015) |
| "Oral flecainide was successful in longer-term management of arrhythmia in 74 and 81% of patients with AV nodal and AV reentrant tachycardia, respectively, and in 83% with atrial tachycardia." | 3.76 | Summary of efficacy and safety of flecainide for supraventricular arrhythmias. ( Anderson, JL; Fredell, PA; Jolivette, DM, 1988) |
| "Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise." | 3.76 | Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. ( Gandhi, MM; Lloyd, G; Taylor, R, 2010) |
| "24 consecutive patients with atrial fibrillation (age 54 (12) years; 5 female, 19 male) developing atrial flutter while taking propafenone (n = 12) or flecainide (n = 12)." | 3.71 | Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. ( Nabar, A; Rodriguez, LM; Timmermans, C; van Mechelen, R; Wellens, HJ, 2001) |
| "We describe two cases of fetal atrial flutter associated with severe fetal hydrops which were unresponsive to digoxin but were successfully treated with flecainide acetate." | 3.70 | Two cases of atrial flutter with fetal hydrops: successful fetal drug therapy. ( Kim, A; Ko, JK; Lee, IS; Lee, PR; Mok, JE; Won, HS; Yoo, HK; Yoo, SJ, 1998) |
| "Flecainide is effective in terminating stable atrial flutter in the conscious dog with a Y-shaped right atrial lesion." | 3.68 | Endocardial mapping of reentry around an anatomical barrier in the canine right atrium: observations during the action of the Class IC agent, flecainide. ( Boyden, PA; Graziano, JN; Pinto, JM, 1993) |
| "The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II)." | 3.68 | Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. ( Hansen, FA; Pedersen, AK; Rasmussen, J; Sihm, I; Thygesen, K, 1990) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 3.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| " We evaluated frequency-dependence of excitability and refractoriness before and after flecainide or procainamide administration in relation to termination of reentrant atrial flutter." | 3.68 | Sustained atrial flutter around the tricuspid valve in pigs: differentiation of procainamide (class IA) from flecainide (class IC) and their rate-dependent effects. ( Bel, KJ; Crijns, HJ; de Langen, CD; Ebels, T; Grandjean, JG; Lie, KI; Wesseling, H, 1993) |
| " To determine the exact role played by these two electrophysiologic effects in the termination of reentry, the effects of disopyramide, flecainide, propafenone and E-4031, a new class III drug, were examined in a canine model of atrial flutter (cycle length 120 +/- 4 to 131 +/- 3 ms) caused by reentry." | 3.68 | Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. ( Inoue, H; Nozaki, A; Sugimoto, T; Yamashita, T, 1991) |
| "Fifty-one consecutive patients with atrial tachycardia [atrial fibrillation (FA) 37, atrial flutter (Fl) 10, tachycardia (TSA) 4] received a single 2 mg/kg dose of flecainide injected intravenously over 5 to 10 minutes." | 3.67 | [Reduction of auricular fibrillation and tachycardia using intravenous flecainide]. ( Aumont, MC; Boujon, B; Charlier, P; Cohen-Solal, A; Dahan, M; Farinotti, P; Jaeger, P; Juliard, JM, 1987) |
| "Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs." | 3.67 | Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate. ( Kim, SS; Ruffy, R; Smith, P, 1988) |
| "Neonatal tachyarrhythmia was observed in 31." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "AFL accounts for 30% of fetal tachyarrhythmias, 11% to 18% of neonatal tachyarrhythmias, and 8% of supraventricular tachyarrhythmias in children older than 1 year of age." | 2.82 | Atrial Flutter in Pediatric Patients. ( Drago, F; Tamborrino, PP, 2022) |
| "We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial treatment strategy of either radiofrequency catheter ablation (146 patients) or therapy with class IC or class III antiarrhythmic agents (148 patients)." | 2.77 | Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. ( Cosedis Nielsen, J; Englund, A; Hansen, PS; Hartikainen, J; Hindricks, G; Johannessen, A; Kongstad, O; Mortensen, LS; Pehrson, S; Raatikainen, P; Walfridsson, H, 2012) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "To identify a possible relationship with subjective symptoms, we reviewed 6319 trans-telephonic electrocardiographic strips (ECGs) recorded from 123 patients in a double-blind, placebo-controlled trial examining dose-response effects of flecainide." | 2.73 | Relationship between subjective symptoms and trans-telephonic ECG findings in patients with symptomatic paroxysmal atrial fibrillation and flutter. ( Atarashi, H; Inoue, H; Ogawa, S, 2008) |
| "Flecainide is a first-line antiarrhythmic drug used to treat atrial arrhythmias and/or supraventricular tachycardia in those without coronary artery disease or structural heart disease." | 2.72 | Perioperative Management of Flecainide: A Problem-Based Learning Discussion. ( Acker, L; Bova Campbell, K; Bronshteyn, YS; Naglee, C; Taicher, B, 2021) |
| "In the not-responders, the mean time to recurrence was 75 +/- 48 days in group C and 75 +/- 62 days in group F(NS)." | 2.68 | [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias]. ( Babuty, D; Brembilla-Perrot, B; Breuillac, JC; Fauchier, JP; Funck, F; Garnier, LF; Maison-Blanche, P; Medvedowsky, JL; Peraudeau, P; Rouesnel, P; Scheck, F, 1997) |
| " Initial oral flecainide dosage was determined by assessing ability to reinitiate SVT after 50 mg, 100 mg, and the total dose of intravenous flecainide had been given." | 2.68 | Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. ( Hellestrand, KJ, 1996) |
| "Seventeen patients had documented recurrence of atrial arrhythmia (9 in the cibenzoline group, 8 in the flecainide group) during the study." | 2.68 | Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study. ( Babuty, D; D'Hautefeuille, B; Mycinsky, C; Peraudeau, P; Pruvost, P; Scheck, F, 1995) |
| "Flecainide (11 patients) was given as an intravenous bolus of 2 mg." | 2.67 | Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. ( Crijns, HJ; Dunselman, PH; Gosselink, AT; Kingma, JH; Lie, KI; Van Gelder, IC, 1994) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "With a probability of success of 90%, a recurrence rate of 5% to 15%, and few complications, catheter ablation emerges as the best treatment of recurrent, symptomatic flutter." | 2.41 | Management of atrial flutter. ( Aass, H; Kongsgaard, E, 2000) |
| "In all, 374 (53." | 1.42 | The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department. ( Clark, D; Cragg, A; Gray, A; Grubb, N; Hamilton, A, 2015) |
| "The flecainide infusion test has been proposed to screen candidates for hybrid pharmacological and ablation therapy." | 1.33 | Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; El Jamal, B; Greco, L; La Rocca, V; Messina, V; Nocerino, P; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 2005) |
| "Syncope was abolished after successful radiofrequency catheter ablation of the AFL." | 1.31 | Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. ( Azegami, K; Hiejima, K; Hirao, K; Horikawa, T; Kawabata, M; Motokawa, K; Suzuki, F; Suzuki, K, 2001) |
| " In this study, we prospectively investigated the effects of AFI ablation and continuation of drug therapy in patients with AF who developed AFI due to long-term administration of class IC antiarrhythmic drugs." | 1.30 | Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. ( Jung, W; Lewalter, T; Lüderitz, B; Schumacher, B; Vahlhaus, C; Wolpert, C, 1999) |
| "Fetal hydrops was seen in 22 patients." | 1.29 | Management outcome and follow-up of fetal tachycardia. ( Brenner, JI; Copel, JA; Kleinman, CS; Meijboom, EJ; Stoutenbeek, P; van Engelen, AD; Weijtens, O, 1994) |
| "Flecainide acetate was given intravenously; administration was stopped because of development of a significant increase in the QRS duration, existence of prominent deep Q waves and marked ST elevation in leads V1 to V4." | 1.28 | Pseudo infarction ECG pattern occurring during intravenous treatment with flecainide acetate. ( Arnold, AE; Burgersdijk, C; Ruiter, JH; van Aubel, KJ, 1992) |
| " Daily flecainide dosage was 200 (100-400) mg." | 1.28 | Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients. ( Frandsen, F; Mickley, H; Møller, M; Pless, P, 1990) |
| "The number of supraventricular tachyarrhythmias recently arisen among patients admitted to the Coronary Care Unit in Piombino, and the results of therapeutical interventions, have been estimated by analysing, retrospectively, the cases pertinent to the period February '84- October '87." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| " The administration of flecainide, dosage 1." | 1.28 | [A case of atrial paralysis during the use of intravenous flecainide acetate]. ( Pardini, E; Tognarini, S, 1989) |
| "Flecainide was administered during tachycardia (over 5 to 10 minutes) to all patients with atrial flutter, to 10 patients with atrial fibrillation, and to 17 patients with ventricular tachyarrhythmias." | 1.27 | Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. ( Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW, 1987) |
| " We report an abnormal pharmacokinetic response to oral as well as intravenous flecainide in a patient who was treated with flecainide for several episodes of atrial flutter." | 1.27 | Abnormal pharmacokinetics of flecainide in a "nonresponder". ( Crijns, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM, 1988) |
| "Flecainide was administered during SVT to 9 patients with atrial flutter, 11 with atrial fibrillation, 7 with atrial tachycardia, 38 with AV reentrant tachycardia and 34 with AV nodal reentrant tachycardia." | 1.27 | Intravenous flecainide acetate for supraventricular tachycardias. ( Hellestrand, KJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (16.35) | 18.7374 |
| 1990's | 41 (39.42) | 18.2507 |
| 2000's | 24 (23.08) | 29.6817 |
| 2010's | 13 (12.50) | 24.3611 |
| 2020's | 9 (8.65) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, JS | 1 |
| Fan, EH | 1 |
| Crijns, HJGM | 1 |
| Elvan, A | 1 |
| Al-Windy, N | 1 |
| Tuininga, YS | 1 |
| Badings, E | 1 |
| Aksoy, I | 1 |
| Van Gelder, IC | 6 |
| Madhavapeddi, P | 1 |
| Camm, AJ | 5 |
| Kowey, PR | 1 |
| Ruskin, JN | 1 |
| Belardinelli, L | 1 |
| Drago, F | 1 |
| Tamborrino, PP | 1 |
| Tiver, KD | 1 |
| Martin, DK | 1 |
| Quah, J | 1 |
| Lahiri, A | 1 |
| Ganesan, AN | 1 |
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Miyoshi, T | 2 |
| Maeno, Y | 2 |
| Hamasaki, T | 2 |
| Inamura, N | 2 |
| Yasukochi, S | 2 |
| Kawataki, M | 2 |
| Horigome, H | 2 |
| Yoda, H | 2 |
| Taketazu, M | 2 |
| Nii, M | 2 |
| Hagiwara, A | 2 |
| Kato, H | 2 |
| Shimizu, W | 2 |
| Shiraishi, I | 2 |
| Sakaguchi, H | 2 |
| Ueda, K | 2 |
| Katsuragi, S | 2 |
| Yamamoto, H | 2 |
| Sago, H | 2 |
| Ikeda, T | 2 |
| Wagner, J | 1 |
| Fitzpatrick, J | 1 |
| Goldschlager, N | 2 |
| Gavin, JL | 1 |
| Peigh, GS | 1 |
| Kim, SS | 2 |
| Acker, L | 1 |
| Bova Campbell, K | 1 |
| Naglee, C | 1 |
| Taicher, B | 1 |
| Bronshteyn, YS | 1 |
| Colangelo, T | 1 |
| Johnson, D | 1 |
| Ho, R | 1 |
| De Bortoli, A | 1 |
| Shi, LB | 1 |
| Ohm, OJ | 1 |
| Hoff, PI | 1 |
| Schuster, P | 1 |
| Solheim, E | 1 |
| Chen, J | 1 |
| Shozu, M | 1 |
| Liberman, L | 1 |
| Starc, TJ | 1 |
| Silver, ES | 1 |
| Comelli, I | 1 |
| Pigna, F | 1 |
| Cervellin, G | 1 |
| Apostolidou, S | 1 |
| Stute, F | 1 |
| Tavares-de-Sousa, M | 1 |
| Hecher, K | 1 |
| Arndt, F | 1 |
| Kozlik-Feldmann, R | 1 |
| Singer, D | 1 |
| Hamilton, A | 1 |
| Clark, D | 1 |
| Gray, A | 1 |
| Cragg, A | 1 |
| Grubb, N | 1 |
| Apps, A | 1 |
| Miller, CP | 1 |
| Fellows, S | 1 |
| Jones, M | 1 |
| Pollet, M | 1 |
| Saeed, M | 1 |
| Atarashi, H | 1 |
| Ogawa, S | 1 |
| Inoue, H | 3 |
| Taylor, R | 1 |
| Gandhi, MM | 1 |
| Lloyd, G | 1 |
| Chung-Esaki, H | 1 |
| Tabas, J | 1 |
| Uzun, O | 1 |
| Babaoglu, K | 1 |
| Sinha, A | 1 |
| Massias, S | 1 |
| Beattie, B | 1 |
| Cosedis Nielsen, J | 1 |
| Johannessen, A | 1 |
| Raatikainen, P | 1 |
| Hindricks, G | 1 |
| Walfridsson, H | 1 |
| Kongstad, O | 1 |
| Pehrson, S | 1 |
| Englund, A | 1 |
| Hartikainen, J | 1 |
| Mortensen, LS | 1 |
| Hansen, PS | 1 |
| Brembilla-Perrot, B | 3 |
| Houriez, P | 1 |
| Claudon, O | 1 |
| Yassine, M | 1 |
| Suty-Selton, C | 1 |
| Vancon, AC | 1 |
| Abo el Makarem, Y | 1 |
| Makarem, E | 1 |
| Courtelour, JM | 1 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 1 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Reisinger, J | 1 |
| Gatterer, E | 1 |
| Lang, W | 1 |
| Vanicek, T | 1 |
| Eisserer, G | 1 |
| Bachleitner, T | 1 |
| Niemeth, C | 1 |
| Aicher, F | 1 |
| Grander, W | 1 |
| Heinze, G | 1 |
| Kühn, P | 1 |
| Siostrzonek, P | 1 |
| Hongo, RH | 1 |
| Themistoclakis, S | 2 |
| Raviele, A | 2 |
| Bonso, A | 2 |
| Rossillo, A | 1 |
| Glatter, KA | 1 |
| Yang, Y | 1 |
| Scheinman, MM | 1 |
| Kanemoto, M | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Esato, M | 1 |
| Ueyama, T | 1 |
| Yoshiga, Y | 1 |
| Kakugawa, H | 1 |
| Kametani, R | 1 |
| Inoue, N | 1 |
| Sawa, A | 1 |
| Matsuzaki, M | 1 |
| Bertaglia, E | 1 |
| Zoppo, F | 1 |
| Proclemer, A | 1 |
| Verlato, R | 1 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Pascotto, P | 1 |
| Turco, P | 2 |
| De Simone, A | 2 |
| La Rocca, V | 2 |
| El Jamal, B | 1 |
| Nocerino, P | 2 |
| Astarita, C | 2 |
| De Matteis, C | 2 |
| Messina, V | 1 |
| Greco, L | 1 |
| Rotunno, R | 1 |
| Di Napoli, T | 2 |
| Vitale, DF | 2 |
| Stabile, G | 2 |
| Sedrakyan, A | 1 |
| Treasure, T | 1 |
| Browne, J | 1 |
| Krumholz, H | 1 |
| Sharpin, C | 1 |
| van der Meulen, J | 1 |
| Scharf, C | 1 |
| Kang, TS | 1 |
| Yoon, YW | 1 |
| Park, S | 1 |
| Hong, BK | 1 |
| Kim, D | 1 |
| Kwon, HM | 1 |
| Kim, HS | 1 |
| Simon, T | 1 |
| Mary-Krause, M | 1 |
| Chatelin, A | 1 |
| Thuault, M | 1 |
| Jaillon, P | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Kawabata, M | 2 |
| Hirao, K | 2 |
| Higuchi, K | 1 |
| Sasaki, T | 1 |
| Furukawa, T | 1 |
| Okada, H | 1 |
| Hachiya, H | 1 |
| Isobe, M | 1 |
| Robinet, S | 1 |
| Melon, R | 1 |
| Piérard, L | 1 |
| Pop, T | 2 |
| Treese, N | 2 |
| Kang, JC | 1 |
| Meinertz, T | 1 |
| Kasper, W | 1 |
| Babuty, D | 2 |
| D'Hautefeuille, B | 1 |
| Scheck, F | 2 |
| Mycinsky, C | 1 |
| Pruvost, P | 1 |
| Peraudeau, P | 2 |
| Crijns, HJ | 6 |
| de Langen, CD | 2 |
| Grandjean, JG | 1 |
| Bel, KJ | 1 |
| Ebels, T | 1 |
| Lie, KI | 7 |
| Wesseling, H | 1 |
| Lee, CY | 1 |
| Teo, WS | 1 |
| Kingma, JH | 4 |
| Dunselman, PH | 1 |
| Gosselink, AT | 1 |
| van Engelen, AD | 1 |
| Weijtens, O | 1 |
| Brenner, JI | 1 |
| Kleinman, CS | 1 |
| Copel, JA | 1 |
| Stoutenbeek, P | 2 |
| Meijboom, EJ | 2 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Pinto, JM | 1 |
| Graziano, JN | 1 |
| Boyden, PA | 1 |
| Ahsan, A | 1 |
| Aldridge, R | 1 |
| Bowes, R | 1 |
| Heldal, M | 2 |
| Orning, OM | 2 |
| Naccarelli, GV | 2 |
| Dorian, P | 1 |
| Hohnloser, SH | 2 |
| Coumel, P | 2 |
| Aliot, E | 2 |
| Denjoy, I | 1 |
| Hopson, JR | 1 |
| Buxton, AE | 1 |
| Rinkenberger, RL | 1 |
| Nademanee, K | 1 |
| Heilman, JM | 1 |
| Kienzle, MG | 1 |
| Hellestrand, KJ | 3 |
| Katritsis, D | 1 |
| Rowland, E | 1 |
| O'Nunain, S | 1 |
| Shakespeare, CF | 1 |
| Poloniecki, J | 1 |
| Reeb, T | 1 |
| de Chillou, C | 1 |
| Sadoul, N | 1 |
| Lacour, JC | 1 |
| Ducrocq, X | 1 |
| Debouverie, M | 1 |
| Weber, M | 1 |
| Aouate, P | 1 |
| Frank, R | 1 |
| Fontaine, G | 1 |
| Tonet, J | 1 |
| Tageddine, R | 1 |
| Benassar, A | 1 |
| Turlure, A | 1 |
| Jacquemin, M | 1 |
| Laborde, JP | 1 |
| De Meester, A | 1 |
| Machiels, JP | 1 |
| Rousseau, L | 1 |
| Luwaert, R | 1 |
| Chaudron, JM | 1 |
| Maison-Blanche, P | 1 |
| Fauchier, JP | 1 |
| Garnier, LF | 1 |
| Rouesnel, P | 1 |
| Breuillac, JC | 1 |
| Funck, F | 1 |
| Medvedowsky, JL | 1 |
| Lawson-Matthew, PJ | 1 |
| Ionescu, A | 1 |
| McHugh, P | 1 |
| Channer, KS | 1 |
| Terrier de la Chaise, A | 1 |
| Jacquemin, L | 1 |
| Beurrier, D | 1 |
| Houplon, P | 1 |
| Louis, P | 1 |
| Danchin, N | 1 |
| Huang, DT | 1 |
| Monahan, KM | 1 |
| Zimetbaum, P | 1 |
| Papageorgiou, P | 1 |
| Epstein, LM | 1 |
| Josephson, ME | 1 |
| Won, HS | 1 |
| Lee, IS | 1 |
| Yoo, HK | 1 |
| Yoo, SJ | 1 |
| Ko, JK | 1 |
| Lee, PR | 1 |
| Kim, A | 1 |
| Mok, JE | 1 |
| Maury, P | 1 |
| Vuille, C | 1 |
| Metzger, J | 1 |
| Veragut, B | 1 |
| Schoenenberger, I | 1 |
| Elamly, A | 1 |
| Chevrolet, JC | 1 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Lewalter, T | 1 |
| Vahlhaus, C | 1 |
| Wolpert, C | 1 |
| Nabar, A | 2 |
| Rodriguez, LM | 2 |
| Timmermans, C | 2 |
| Smeets, JL | 1 |
| Wellens, HJ | 2 |
| Dubrey, SW | 1 |
| Kurbaan, AS | 1 |
| Kaddoura, S | 1 |
| Schwartz, M | 1 |
| Maglio, C | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Boccadamo, R | 1 |
| Dell'Orfano, JT | 1 |
| Wolbrette, DL | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Kongsgaard, E | 1 |
| Aass, H | 1 |
| Wirth, KJ | 1 |
| Knobloch, K | 1 |
| Horikawa, T | 1 |
| Suzuki, K | 1 |
| Motokawa, K | 1 |
| Suzuki, F | 1 |
| Azegami, K | 1 |
| Hiejima, K | 1 |
| van Mechelen, R | 1 |
| Maresca, F | 1 |
| Stabile, E | 1 |
| Oudijk, MA | 1 |
| Ambachtsheer, EB | 1 |
| Zabel, M | 1 |
| Suttorp, MJ | 3 |
| van Aubel, KJ | 1 |
| Ruiter, JH | 1 |
| Arnold, AE | 1 |
| Burgersdijk, C | 1 |
| Frandsen, F | 1 |
| Pless, P | 1 |
| Mickley, H | 1 |
| Møller, M | 1 |
| Hughes, MM | 1 |
| Trohman, RG | 1 |
| Simmons, TW | 1 |
| Castle, LW | 1 |
| Wilkoff, BL | 1 |
| Morant, VA | 1 |
| Maloney, JD | 1 |
| Pritchett, EL | 1 |
| DaTorre, SD | 1 |
| Platt, ML | 1 |
| McCarville, SE | 1 |
| Hougham, AJ | 1 |
| Pietersen, AH | 1 |
| Hellemann, H | 1 |
| Yamashita, T | 2 |
| Usui, M | 1 |
| Nozaki, A | 2 |
| Sugimoto, T | 2 |
| Van Gilst, WH | 4 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Sihm, I | 1 |
| Hansen, FA | 1 |
| Rasmussen, J | 1 |
| Pedersen, AK | 1 |
| Thygesen, K | 1 |
| Feld, GK | 1 |
| Chen, PS | 1 |
| Nicod, P | 1 |
| Fleck, RP | 1 |
| Meyer, D | 1 |
| Bashir, Y | 1 |
| Jessurun, ER | 1 |
| Lie-A-Huen, L | 2 |
| van Hemel, NM | 1 |
| Van Wijk, LM | 3 |
| Mast, EG | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Hamer, HP | 1 |
| Tognarini, S | 1 |
| Pardini, E | 1 |
| Nathan, AW | 1 |
| Bexton, RS | 1 |
| Lau, CP | 1 |
| Davies, DW | 1 |
| Mehta, D | 1 |
| Ward, DW | 1 |
| Cohen-Solal, A | 1 |
| Juliard, JM | 1 |
| Jaeger, P | 1 |
| Farinotti, P | 1 |
| Dahan, M | 1 |
| Charlier, P | 1 |
| Boujon, B | 1 |
| Aumont, MC | 1 |
| Marwick, TH | 1 |
| Woodhouse, SP | 1 |
| Smith, P | 1 |
| Ruffy, R | 1 |
| Anderson, JL | 1 |
| Jolivette, DM | 1 |
| Fredell, PA | 1 |
| Chouty, F | 1 |
| Leclercq, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation[NCT03539302] | Phase 2 | 170 participants (Actual) | Interventional | 2018-05-29 | Completed | ||
| Cryoballoon Pulmonary Vein Isolation as First Line Treatment for Typical Atrial Flutter[NCT03401099] | 113 participants (Actual) | Interventional | 2018-08-17 | Completed | |||
| Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective Multicentre Study (MANTRA-PAF)[NCT00133211] | Phase 3 | 294 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Radiofrequency vs Cryoballoon Catheter Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation - Effect on Atrial Fibrillation Burden Assessed by Implantable Cardiac Monitor (RACE-AF Trial)[NCT03805555] | 105 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences[NCT03162120] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)) | ||
| Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)[NCT04190186] | 90 participants (Anticipated) | Interventional | 2020-06-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for flecainide and Auricular Flutter
| Article | Year |
|---|---|
Atrial Flutter in Pediatric Patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Child; Child, Preschool; D | 2022 |
Perioperative Management of Flecainide: A Problem-Based Learning Discussion.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Flecainide; Humans; Problem-Based Learning; Tachycardia, Sup | 2021 |
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: evidence from randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Th | 1995 |
[Severe flecainide acetate poisoning. Apropos of a case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Biological Availability; Calcium Gluconate | 1999 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Management of atrial flutter.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrophysiologic Techniques, C | 2000 |
[Protocols for the treatment of supraventricular tachycardias in the fetus].
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Drug Therapy, Combination; Fema | 2001 |
Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Meta-Analysis as Topi | 1992 |
Summary of efficacy and safety of flecainide for supraventricular arrhythmias.
Topics: Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Flecainide; Humans; Tachycardia, Supr | 1988 |
24 trials available for flecainide and Auricular Flutter
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Relationship between subjective symptoms and trans-telephonic ECG findings in patients with symptomatic paroxysmal atrial fibrillation and flutter.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Electrocardiograph | 2008 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit Analysis; Female; Flecaini | 2004 |
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Administration Schedule; Dru | 2004 |
[Flecainide controlled-release for prevention of atrial fibrillation relapse].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Delayed-Action Preparations; Elec | 2006 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Drug Toleran | 1995 |
Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Double-Blind Method; Echocardiography; Electrocardiography; | 1994 |
Effects of flecainide on termination of atrial flutter by rapid atrial pacing.
Topics: Adult; Aged; Aged, 80 and over; Atrial Flutter; Cardiac Pacing, Artificial; Combined Modality Therap | 1993 |
Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Flecainid | 1996 |
Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; F | 1996 |
Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmia | 1996 |
Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; A | 1996 |
[Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans | 1997 |
Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atria | 2001 |
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.
Topics: Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Female; Flecainide; Humans; Male; Middle Aged; | 1992 |
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Double-Blind Method; F | 1991 |
Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiography; Female; Flec | 1991 |
Clinical trials of flecainide acetate in the management of supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans; | 1990 |
The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainide; Humans; Male; Middle A | 1990 |
Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Female; Flecainide; Hear | 1989 |
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1989 |
Summary of efficacy and safety of flecainide for supraventricular arrhythmias.
Topics: Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Flecainide; Humans; Tachycardia, Supr | 1988 |
68 other studies available for flecainide and Auricular Flutter
| Article | Year |
|---|---|
Toxic Effects of Flecainide in a Patient With Kidney Failure and Tachyarrhythmia.
Topics: Aged; Atrial Flutter; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Flecainide; | 2021 |
Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Flecainide; Huma | 2022 |
Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Block; Diltiazem; Elec | 2023 |
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
VT or Not VT?: That Is the Question.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Drug-Related Side Effects and Adverse Reactions; Elect | 2020 |
Paroxysmal Atrial Fibrillation on Flecainide Therapy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Flecainide; Humans | 2020 |
Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Electrocardiogra | 2021 |
Incidence and clinical predictors of subsequent atrial fibrillation requiring additional ablation after cavotricuspid isthmus ablation for typical atrial flutter.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 2017 |
Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Child Development; Child, Preschool; Digoxin; Drug Therapy, | 2017 |
Usefulness of High-Dose Oral Flecainide for Termination of Recent-Onset Atrial Fibrillation in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Fe | 2018 |
1:1 atrial flutter induced by flecainide, whilst the patient was at rest.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Emergency Service, Hospital; Flecainide; H | 2018 |
Topics: Atrial Flutter; Cardiotocography; Cesarean Section; Dose-Response Relationship, Drug; Electric Count | 2018 |
The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2015 |
Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2015 |
Proarrhythmic Antiarrhythmic.
Topics: Action Potentials; Anti-Arrhythmia Agents; Atrial Flutter; Atrioventricular Node; Catheter Ablation; | 2016 |
Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Flecainide; Heart Block; Humans | 2010 |
ST-segment elevation in a patient receiving flecainide.
Topics: Adenosine; Anti-Arrhythmia Agents; Atrial Flutter; Diagnosis, Differential; Electrocardiography; Fle | 2011 |
Rapid control of foetal supraventricular tachycardia with digoxin and flecainide combination treatment.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Drug Therapy, Combination; Echoc | 2012 |
[Can the supraventricular proarrhythmic effects of class 1C antiarrhythmic drugs be prevented with the association of beta blockers?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Flutter; Female; Flecainide; Humans; Imi | 2000 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Electrophysiologic Techniques, C | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Combined Modality Th | 2005 |
A case of acute ventricular capture threshold rise associated with flecainide acetate.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Flecainide; Hu | 2006 |
Clinical and electrophysiological characteristics of patients having atrial flutter with 1:1 atrioventricular conduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Case | 2008 |
[Clinical case of the month. Atrial flutter with rapid ventricular response (1:1 atrioventricular conduction) caused by flecaïnide].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Electric Counter | 2007 |
Effect of intravenous flecainide on atrial vulnerability in man.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1983 |
Sustained atrial flutter around the tricuspid valve in pigs: differentiation of procainamide (class IA) from flecainide (class IC) and their rate-dependent effects.
Topics: Animals; Atrial Flutter; Electrocardiography; Flecainide; Heart Conduction System; Male; Procainamid | 1993 |
Electrocardiographic case. Irregular broad complex tachycardia. Wolff-Parkinson-White syndrome with atrial flutter-fibrillation.
Topics: Atrial Fibrillation; Atrial Flutter; Diagnosis, Differential; Electrocardiography; Flecainide; Human | 1994 |
Management outcome and follow-up of fetal tachycardia.
Topics: Atrial Flutter; Digoxin; Echocardiography; Female; Fetal Diseases; Fetal Heart; Flecainide; Follow-U | 1994 |
Endocardial mapping of reentry around an anatomical barrier in the canine right atrium: observations during the action of the Class IC agent, flecainide.
Topics: Animals; Atrial Flutter; Atrial Function; Dogs; Endocardium; Flecainide; Heart Conduction System; Ta | 1993 |
1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide.
Topics: Aged; Amiodarone; Atrial Flutter; Atrioventricular Node; Digoxin; Drug Therapy, Combination; Electro | 1993 |
Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Dose | 1995 |
[Atrial electrophysiological study of unexplained ischemic cerebrovascular disorders].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Cere | 1995 |
Unusual atrial pro-arrhythmic effect of flecainide: a contemporary review.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography, Ambulatory; Female; Flecainide; H | 1996 |
Evaluation of a protocol to select patients of all ages for cardioversion from atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronar | 1997 |
[Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Electrocardiography; Female; Flecainide; | 1997 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 1998 |
Two cases of atrial flutter with fetal hydrops: successful fetal drug therapy.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Female; Flecainide; Humans; Hydrops Fetalis; | 1998 |
Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 1999 |
Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cath | 1999 |
Atrial flutter in a young man with a highly competitive and stressful occupation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Dietary Supplements; Flecainide; Humans; Male; Occupa | 1999 |
Implantable atrial defibrillator and detection of atrial flutter.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable; Electrocar | 2000 |
Atrial defibrillation at the millennium: new challenges for evolving technology.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable; Equipment | 2000 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, L | 2001 |
Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrocardiography; Electrophysio | 2001 |
Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Electro | 2001 |
Pseudo infarction ECG pattern occurring during intravenous treatment with flecainide acetate.
Topics: Aged; Atrial Flutter; Bundle-Branch Block; Electrocardiography; Female; Flecainide; Humans; Infusion | 1992 |
Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutte | 1990 |
Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function.
Topics: Atrial Fibrillation; Atrial Flutter; Female; Flecainide; Follow-Up Studies; Humans; Male; Middle Age | 1992 |
Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Dogs; Flecainide; Heart Conduction Sy | 1991 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Disopyramide; Dogs; Ele | 1991 |
Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Huma | 1990 |
Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Encainide; Female; Flec | 1990 |
Effects of flecainide on the atrial defibrillation threshold.
Topics: Atrial Fibrillation; Atrial Flutter; Electric Countershock; Female; Flecainide; Humans; Male; Middle | 1989 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
[Atrial flutter with 1:1 AV conduction during intravenous flecainide treatment].
Topics: Aged; Atrial Flutter; Electrocardiography; Flecainide; Humans; Injections, Intravenous; Male | 1989 |
[A case of atrial paralysis during the use of intravenous flecainide acetate].
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecai | 1989 |
Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainid | 1987 |
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Electrocardiography; Flecainide; | 1987 |
[Reduction of auricular fibrillation and tachycardia using intravenous flecainide].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Flecainide; Heart Atria; Hemo | 1987 |
Use of flecainide acetate in the treatment of supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Tachycardia, Paroxysm | 1988 |
Abnormal pharmacokinetics of flecainide in a "nonresponder".
Topics: Administration, Oral; Adult; Atrial Flutter; Electrocardiography; Flecainide; Humans; Injections, In | 1988 |
Intravenous flecainide acetate for supraventricular tachycardias.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1988 |
Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1988 |
[Value of flecainide in supraventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial F | 1986 |
Effect of intravenous flecainide on atrial vulnerability in man.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Electrocardio | 1985 |